Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Jennifer A Kowalski

David S Thomson

Robert Sibley

Rene Marc Lemieux

Erick Richard Roush Young

Ronald John Sorcek

Daniel Richard Marshall

Steven Richard Brunette

Matt Aaron Tschantz

Craig Andrew Miller

Bryan Patrick McKibben

Joerg Bentzien

Sabine K Schlyer

Joshua Courtney Horan

Michael David Lawlor

John R Regan

Weimin Liu

Neil Moss

Daniel Kuzmich

Derek Cogan

Abdelhakim Hammach

Michael Jason Burke

Zhaoming Xiong

Zhidong Chen

Yunlong Zhang

Donghong Amy Gao

Rajashekhar Betageri

Anthony S Prokopowicz

Brian Nicholas Cook

Xiang Li

Alexander Heim-Riether

Ingo Andreas Mugge

Fariba Soleymanzadeh

Darren DiSalvo

Frank Wu

Hui Yu

Mark Stephen Ralph

Di Wu

Antonio J M Barbosa, Jr

Yang Yu

Antonio Jose Del Moral Barbosa, Jr

Lana Louise Smith-Keenan

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

Anthony S Iii Prokopowicz

Antonio JM Barbosa

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Rho kinase inhibitors

Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

[object Object]

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Rto R, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

CXCR3 receptor antagonists

Compounds of Formula (I) wherein R, R, R, R, R, R, and Rare as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Compounds of Formula (IA) and (IB) wherein R, R, R, A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

Growing community of inventors

New Milford, CT, United States of America

Jennifer A Kowalski